SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia shares are under pressure as traders react to the boards investigation into Jensen Huangs admitted affair with a businesswoman reported to have suspected ties to Chinese intelligence, raising concerns about governance, possible information leaks, and Huangs future as CEO. The community is divided between seeing the probe and leadership uncertainty as a serious overhang and treating the controversy as unrelated to Nvidias AI-chip business and a buying opportunity.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is under heavy selling pressure ahead of its Q3 earnings report, with traders speculating about a possible leak while others see the decline as pre-report positioning; a leak is unconfirmed. Bulls point to growth and potential upbeat guidance, while bears worry that the Eli Lilly obesity-drug deal could pressure margins and profitability.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics quarterly revenue beat and higher full-year outlook, driven by BRIUMVI growth, are the main focus; shares saw a sharp post-results dip and recovery, prompting debate over a sell the news reaction versus short-driven volatility. Traders are also watching for Phase 3 results on subcutaneous BRIUMVI as a next potential catalyst.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

IWMs sharp rally is drawing attention as small caps outperform, with traders describing a possible low-volume short squeeze and rotation into the Russell 2000. Bulls are chasing calls and citing hopes for easing inflation, while skeptics question the moves strength given reported weak flows and limited volume.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors pending FDA decision on deramiocel for Duchenne muscular dystrophy, focused on the amended upper-limb-function evidence from HOPE-3, is driving attention ahead of the Nov. 22 PDUFA date. Bulls cite the trial data and a letter urging approval from 28 investigators, while skeptics point to FDA scrutiny and the earlier negative advisory-panel vote on the cardiac indication; short-squeeze speculation adds to the debate.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMDs rally is drawing attention after Oppenheimer upgraded the stock, while Google Clouds use of EPYC processors in its AI infrastructure added a company-specific catalyst. Traders also point to money rotating from Nvidia amid a CEO-related investigation, though some see the move as sentiment-driven and question AMDs valuation.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candels SITC findings on immune activation and viral clearance, alongside its positive Phase 3 prostate-cancer results, are drawing attention as the company prepares a BLA for CAN-2409. Bulls see the data as supportive of the regulatory package, while skeptics question filing and manufacturing execution and warn of a possible sell-the-news reaction.

Axon Enterprise, Inc. engages in the development, manufacture, and sale of conducted electrical weapons for personal defense. It operates through the TASER segment and Software and Sensors segment. The TASER segment sells conducted electrical weapons, accessories, and other related products and services. The Software and Sensors segment includes devices, wearables, applications, cloud, and mobile products. The company was founded by Patrick W. Smith and Thomas P. Smith on September 7, 1993 and is headquartered in Scottsdale, AZ.

Axon Enterprise Inc

A quarterly earnings shortfall and reduced full-year revenue guidance, tied largely to federal Dedrone drone deployments being delayed, have driven a sharp selloff. Traders debate whether the decline overreacts to a timing issue or reflects high valuation and weaker near-term growth, with some buying the dip and others expecting further downside.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk shares are rallying sharply ahead of its Q3 earnings report, with traders speculating about short covering and an earnings leak, though neither explanation is confirmed. The move has fueled hopes for a turnaround, while many investors worry that weak results or guidance could erase the gains.

Churchill Capital Corp. XI is a blank check company. It was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded by Michael Stuart Klein on June 4, 2025 and is headquartered in New York, NY.

Agility Robotics Inc.

Agility Robotics Inc. - Ordinary Shares - Class A

Post-merger selling in Agility Robotics is drawing attention, with traders pointing to typical de-SPAC volatility and questioning the companys steep losses, limited revenue, and path to commercial scale. Some remain bullish on humanoid robotics and the companys reported orders, but the discussion is dominated by skepticism about valuation and near-term execution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Milestone Gets China Approval For Etripamil Nasal Spray

(RTTNews) - Milestone Pharmaceuticals (MIST) on Thursday announced that China's National Medical Products Administration has approved etripamil nasal spray for treating paroxysmal supraventricular tachycardia (PSVT) in adults. Etripamil is marketed in the U.S. as CARDAMYST...

Milestone Pharma Announces Approval Of Etripamil Nasal Spray In China; Triggers Milestone Payment

(RTTNews) - Milestone Pharmaceuticals Inc. (MIST) announced that China's National Medical Products
Administration has approved etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia in adults. The NMPA decision marks the first regulatory approval of e...

Milestone Pharmaceuticals (MIST) Reports Q2 Loss, Lags Revenue Estimates

Milestone Pharmaceuticals (MIST) delivered earnings and revenue surprises of -16.67% and -30.13%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

After Plunging 20.2% in 4 Weeks, Here's Why the Trend Might Reverse for Milestone Pharmaceuticals (MIST)

Milestone Pharmaceuticals (MIST) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Alpha Cognition Announces Election of Dr. Robert Wills as Chairman of the Board

Alpha Cognition Inc. (Nasdaq: ACOG) (Alpha Cognition, or the Company), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced changes to its Board of Directors. Robert Wills has been elected Chairman of the Board, succeeding...

Milestone Pharmaceuticals (MIST) Reports Q1 Loss, Lags Revenue Estimates

Milestone Pharmaceuticals (MIST) delivered earnings and revenue surprises of -433.33% and -99.68%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Milestone Pharmaceuticals (MIST) Projected to Post Earnings on Wednesday

Milestone Pharmaceuticals (NASDAQ:MIST) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 13. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-13-milestone-pharmaceuticals-inc-stock...

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Short Interest Update

Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) saw a large increase in short interest in the month of April. As of April 15th, there was short interest totaling 10,325,577 shares, an...

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Average Rating of "Moderate Buy" from Analysts

Shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) have been assigned an average rating of "Moderate Buy" from the six brokerages that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has...

Insider Selling: Milestone Pharmaceuticals (NASDAQ:MIST) CEO Sells 36,500 Shares of Stock

Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) CEO Joseph Oliveto sold 36,500 shares of the firm's stock in a transaction dated Thursday, April 16th. The stock was sold at an average...

This account has been verified as an official MIST representative.

Verified Account

Milestone Pharma ($MIST)

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is an emerging commercial-stage biopharmaceutical company advancing innovative cardiovascular medicines to benefit people living with certain heart conditions. Milestone’s lead product is CARDAMYST® (etripamil) nasal spray, a novel calcium channel blocker, which is FDA-approved for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. Etripamil is also in Phase 3 development for the control of symptomatic episodic attacks associated with AFib-RVR. https://milestonepharma.com/

Milestone Pharmaceuticals Inc

MIST Stock Soars Pre-Market After FDA Approves First Commercial Product – Retail Remains Bullish, Dismisses ‘Sell The News’ Concerns

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>Milestone announced that the FDA approved Cardamyst, a novel nasal spray designed to rapidly resolve episodes of Paroxysmal Supraventricular Tachycardia and restore sinus rhythm.</li><li>The nasal spray can be self-administered by patients outside the emergency department or other healthcare settings, the company said.</li><li>Milestone expects Cardamyst to be available for purchase at retail pharmacies in the first quarter of 2026.</li></ul>Shares of Milestone Pharmaceuticals Inc. (MIST) rose nearly 32% in Monday’s pre-market after the company received approval from the U.S. Food and Drug Administration (FDA) for its first commercial product late Friday.Milestone announced that the FDA approved Cardamyst, a novel nasal spray designed to rapidly resolve episodes of Paroxysmal Supraventricular Tachycardia (PSVT) and restore sinus rhythm.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/MIST">Milestone stock</a> trended in the ‘extremely bullish’ territory, while message volumes were at ‘extremely high’ levels at the time of writing.<h2 class="st-heading-2">Cardamyst Approval</h2>Milestone stated in its announcement that the approval of Cardamyst opens up an addressable market of more than two million Americans who suffer from PSVT. The nasal spray can be self-administered by patients outside the emergency department or other healthcare settings, the company said.Milestone expects Cardamyst to be available for purchase at retail pharmacies in the first quarter (Q1) of 2026.“Cardamyst is a novel at-the-ready treatment option that addresses the unpredictable impact of PSVT by offering patients the freedom to manage episodes anytime and anywhere,” said Joseph Oliveto, CEO, Milestone Pharmaceuticals.<h2 class="st-heading-2">Clinical Data</h2>Milestone stated that Cardamyst’s approval by the FDA is based on safety data from more than 1,800 participants and over 2,000 episodes of PSVT.The company said that participants using Cardamyst were twice as likely to convert symptomatic PSVT to sinus rhythm and did so more than three times faster than with a placebo.<h2 class="st-heading-2">Retail Optimistic</h2>Retail users on Stocktwits expressed their optimism around the company and Cardamyst following the FDA approval.One user said that the most challenging part for the company was over after the approval, adding that those who are long on the stock have “ZERO to worry about here.”<stembedurl>https://stocktwits.com/Wut_About_Bob/message/639158529</stembedurl>Another user dismissed concerns that this is a “sell the news” event, adding that they are “waiting with 0 worries.”<stembedurl>https://stocktwits.com/MarketILF/message/639154331</stembedurl><a href="https://stocktwits.com/symbol/MIST">MIST stock</a> is up 2% year-to-date and 30% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tsla-stock-fully-priced-for-autonomy-ev-demand-weakens-gary-black/cLeECtqRE8s">Is TSLA Stock Fully Priced For Autonomy? Here's What Gary Black Thinks</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a trending stock chart.

Milestone stated in its announcement that the approval of Cardamyst opens up an addressable market of more than two million Americans who suffer from PSVT.

Buying the dip

Selling or trimming

Holding

Waiting for the investigation results to decide

Nvidia ($NVDA) is down about 4% after its board opened an investigation into CEO Jensen Huang. What are you doing with the stock?

Stocktwits

) is down about 4% after its board opened an investigation into CEO Jensen Huang. What are you doing with the stock?

Current Price	$0.7785
Prev Close	$0.7628
Open	$0.761
Dividend Yield	0.00%
50-Day Moving Average	$0.8538
Beta	1.75
Avg. Volume	938,349.60
PE Ratio	-1.10

52-Week High	$3.06
52-Week Low	$0.6307
Market Capitalization	$94.97M
EPS (Annual)	-$0.7517
Price to Book	5.21
Revenue Per Employee	$40,684.21

Feed

News

Sentiment

Earnings

Fundamentals

Info

MIST Fundamentals